What are the Topics You Care about Making Trials in Lupus More Effective? Results of an Open Space Meeting of International Lupus Experts
Fecha
2021-05-20Autor
Mucke, Johanna
Alarcón Riquelme, Marta
Andersen, Jeanette
Aringer, Martin
Bombardieri, Stefano
Brinks, Ralph
Cervera, Ricard
Chehab, Gamal
Cornet, Alain
Costedoat Chalumeau, Nathalie
Czirják, László
Doria, Andrea
Fischer Betz, Rebecca
Furie, Richard A.
Gatto, Mariele
Houssiau, Frédéric A.
Ines, Luis
Liang, Matthew H.
Morand, Eric
Mosca, Marta
Pego Reigosa, José María
Rúa Figueroa, Iñigo
Ruiz Irastorza, Guillermo
Terrier, Benjamin
Voss, Anne
Schneider, Matthias
Metadatos
Mostrar el registro completo del ítem
Lupus Science and Medicine 8(1) : (2021) // Article ID e000506
Resumen
Despite promising candidates for new therapeutic options in the treatment of systemic lupus erythematosus (SLE), many clinical trials have failed in the past few years. The disappointing results have been at least partly be attributed to trial designs. With the aim of stimulating new developments in SLE trial design, an international open space meeting was held on occasion of the European Lupus Meeting 2018 in Duesseldorf, Germany about ‘What are the topics you care about for making trials in lupus more effective?’. The Open Space is a participant-driven technology, where the discussion topics and schedule are selected during the meeting by all participants and discussion rounds are led by the people attending encouraging active contributions. Eleven topics were selected for further discussion, of which 6 were voted to be more intensively discussed in two consecutive rounds. Major topics were the optimal handling of glucocorticoids in clinical trials, the improvement of outcome measures, reducing or controlling the placebo response and the identification of biomarkers and stratification parameters. Further, the importance of local and international networks was emphasised. By networking, collaborations are facilitated, patient recruitment is more efficient and treatment can be harmonised thus lead to more successful SLE trials. Further discussions are needed to substantiate the results and develop new trial designs.